Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699596 | 0.89 | MDM2 (0.44) | MDM2CYP3A4LMNAMAPK1CYP3A5 | |
| SCHEMBL13699585 | 0.86 | MLNR (0.46) | MDM2CYP3A4LMNAMAPK1CYP3A5 | |
| SCHEMBL13699589 | 0.85 | MDM2 (0.41) | MDM2CYP3A4LMNAMAPK1CYP3A5 | |
| SCHEMBL13699581 | 0.84 | MLNR (0.47) | MDM2CYP3A4 | |
| SCHEMBL13699584 | 0.84 | MLNR (0.47) | MDM2CYP3A4 | |
| SCHEMBL13699604 | 0.84 | MDM2 (0.41) | MDM2 | |
| SCHEMBL13699609 | 0.84 | MDM2 (0.41) | MDM2 | |
| SCHEMBL4167201 | 0.82 | MDM2 (0.47) | MDM2CYP3A4LMNAMAPK1CYP3A5 | |
| SCHEMBL4167196 | 0.82 | MDM2 (0.47) | MDM2CYP3A4LMNAMAPK1CYP3A5 | |
| SCHEMBL13699597 | 0.82 | MDM2 (0.42) | MDM2CYP3A4LMNAMAPK1CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885CYP3A4 1990/4885LMNA 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.